RUBY NASDAQ
Rubius Therapeutics, Inc.
1W: +185.0%
1M: +214.9%
3M: +251.8%
1Y: -76.2%
3Y: -99.3%
5Y: -99.6%
$0.06
Last traded 2023-12-29 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0032-0.3763
Volume755,858
Avg Volume94,063
Beta2.21
Dividend—
Analyst Ratings
Company Info
CEOLaurence A. Turka
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-18
Websiterubiustx.com
399 Binney Street
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617 679 9600
About Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Appelhans Dannielle | S-Sale | 10,385 | $0.13 | 2023-02-24 |
| CAGNONI PABLO J | S-Sale | 8,448 | $0.25 | 2023-02-01 |
| Appelhans Dannielle | S-Sale | 3,878 | $0.25 | 2023-02-01 |
| Appelhans Dannielle | M-Exempt | 7,500 | — | 2023-01-31 |
| Appelhans Dannielle | M-Exempt | 7,500 | — | 2023-01-31 |